Login or sign up
For business
Average ratingGreat
4.1/ 5

Based on 7 reviews

543%
429%
329%
20%
10%
Ask AI

Questions about Combigene

Based on 7 reviews, listing data and website checks · updated 3 days ago

What is Combigene?

CombiGene is a biotechnology company based in Lund, Skåne County, Sweden, that develops gene therapies for severe life-altering diseases. They are currently creating a breakthrough therapy using an adeno-associated viral vector (AAV) to treat epilepsy patients by administering neuropeptide Y (NPY) and its receptor Y2 directly to the brain. Their goal is to provide effective treatment where adequate options are currently lacking.

What themes do multiple reviewers share about their experience with Combigene?

Reviewers consistently praise the team's professionalism, knowledge, and responsiveness. Common themes include high-quality results, efficient project handling, and excellent service delivery. Some users also noted that the team promptly answered questions and provided great solutions for business needs.

Who exactly is Combigene targeting with its services?

The company is designed for patients affected by severe life-altering diseases, particularly those with epilepsy for whom current treatments are inadequate. They are also suitable for businesses or partners looking for high-quality biotechnology solutions and professional collaboration in gene therapy development.

Where is Combigene located?

Combigene is based in Lund, Skåne County.

What is the official website of Combigene?

The official website of Combigene is combigene.com.

How is Combigene rated on Trustburn?

On Trustburn, Combigene has a rating of 4.1 out of 5 based on 7 reviews.

Is Combigene on social media?

Combigene has official profiles on Linkedin.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Combigene

CombiGene provides patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies.

CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. CombiGene is developing a breakthrough therapy with the potential to dramatically improve the quality of life for a group of epilepsy patients for whom there is currently no effective treatment. CombiGene uses an adeno-associated viral vector (AAV) to administer a combination of neuropeptide Y (NPY) and its receptor Y2 directly to the part of the brain where the epileptic seizure begins. The most important preclinical effect studies have been concluded with positive results and the next step will be the compulsory safety studies. Given a positive outcome from the safety studies and successful GMP production of CG01, studies in humans can begin.

Categories
Biotechnology